SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): January 2, 2004
Ciphergen Biosystems, Inc.
(Exact name of Registrant as specified in its charter)
Delaware 000-31617 33-059-5156
(State or other jurisdiction of [Commission File (I.R.S. Employer
incorporation or organization) Number] Identification Number)
6611 Dumbarton Circle
Fremont, CA 94555
(Address of principal executive offices)
(510) 505-2100
(Registrant's telephone number, including area code)
The information in this Current Report on Form 8-K, including the
exhibits, is furnished pursuant to Item 9 - Regulation FD Disclosure and shall
not be deemed "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities under that
Section. Furthermore, the information in this Current Report on Form 8-K,
including the exhibits, shall not be deemed to be incorporated by reference into
the filings of Ciphergen Biosystems, Inc. under the Securities Act of 1933, as
amended.
Item 9. Regulation FD Disclosure
A copy of the press release issued January 2, 2004 by the Registrant
announcing a preliminary forecast for Fourth Quarter 2003 earnings is furnished
under Item 9 of this Current Report on Form 8-K as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Ciphergen Biosystems, Inc.
(Registrant)
Date: January 2, 2004 By: /s/ William Rich
-------------------------------------
William E. Rich
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number Description
------- --------------------------------------------------------------
99.1 Press Release issued by Ciphergen Biosystems, Inc. on January
2, 2004